Antigenemia is common among children with rotavirus disease. Because obtaining stool specimens is cumbersome, we evaluated whether detection of antigenemia in sera obtained during routine clinical practice could augment rotavirus surveillance to assess the effect of vaccination.
We determined the sensitivity, specificity, and positive and negative predictive values of serum/plasma rotavirus antigen detection using fecal antigen positivity as the gold standard. Fecal specimens obtained by active surveillance and residual serum/plasma specimens obtained during routine clinical testing from children 15 days to 23 months of age presenting with acute gastroenteritis (AGE) to a children's hospital in Houston were tested for rotavirus using a commercially available enzyme immunoassay. Using case-control methods, we compared vaccine effectiveness (VE) using cases identified through serum/plasma testing versus stool testing.
Of the 205 AGE patients with fecal specimens, 71 (35%) had a serum/plasma sample available. Among these 71 children, antigenemia was detected in 22 of 29 with rotavirus-positive fecal specimens (sensitivity = 75%; 95% confidence interval [CI] = 60%–91%) versus 2 of 42 children with rotavirus-negative fecal specimens (specificity = 95%; 95% CI = 89%–100%). The positive and negative predictive values of rotavirus antigenemia were 92% (95% CI = 81%–100%) and 85% (95% CI = 75%–95%), respectively. Thirty-four of 195 children with AGE without fecal specimens had serum/plasma available; 10 (29%) had rotavirus antigenemia. Three-dose VE using cases identified through serum/plasma testing was similar (VE = 84%; 95% CI = 25%–96%) to that using cases identified though fecal testing (VE = 85%; 95% CI = 55%–95%).
Detection of antigenemia in routinely collected serum/plasma could augment identification of rotavirus disease for postlicensure evaluation of impact and effectiveness of rotavirus vaccination.
From the *Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA; †Center for Vaccine Awareness and Research, Texas Children's Hospital, Houston, TX; ‡Department of Pediatrics, Baylor College of Medicine, Houston, TX; §Immunization Project, Texas Children's Hospital, Houston, TX; and ¶Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX.
Accepted for publication March 9, 2010.
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention (CDC).
Address for correspondence: Manish Patel, MD, MSc, Viral Gastroenteritis Section, MS-A47, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30333. E-mail: Aul3@cdc.gov.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.pidj.com).